Andrew M. Anisfeld

2.0k total citations · 1 hit paper
10 papers, 1.6k citations indexed

About

Andrew M. Anisfeld is a scholar working on Oncology, Surgery and Molecular Biology. According to data from OpenAlex, Andrew M. Anisfeld has authored 10 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 5 papers in Surgery and 5 papers in Molecular Biology. Recurrent topics in Andrew M. Anisfeld's work include Drug Transport and Resistance Mechanisms (7 papers), Cholesterol and Lipid Metabolism (4 papers) and Rheumatoid Arthritis Research and Therapies (3 papers). Andrew M. Anisfeld is often cited by papers focused on Drug Transport and Resistance Mechanisms (7 papers), Cholesterol and Lipid Metabolism (4 papers) and Rheumatoid Arthritis Research and Therapies (3 papers). Andrew M. Anisfeld collaborates with scholars based in United States, Netherlands and Sweden. Andrew M. Anisfeld's co-authors include Heidi R. Kast-Woelbern, Peter A. Edwards, Timothy M. Willson, Stacey A. Jones, Bryan Goodwin, Paul T. Tarr, Peter Tontonoz, Puiying A. Mak, John B. Hogenesch and John M. Rosenfeld and has published in prestigious journals such as Journal of Biological Chemistry, Molecular Cell and Journal of Lipid Research.

In The Last Decade

Andrew M. Anisfeld

10 papers receiving 1.6k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Regulation of Multidrug Resistance-associated Protein 2 (ABCC2) by the Nuclear Receptors Pregnane X Receptor, Farnesoid X-activated Receptor, and Constitutive Androstane Receptor

2002 723 citations Heidi R. Kast-Woelbern, Bryan Goodwin et al. Journal of Biological Chemistry profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Andrew M. Anisfeld United States	8	1.0k	684	542	391	261	10	1.6k
Diane Stroup United States	17	1.0k 1.0×	901 1.3×	745 1.4×	274 0.7×	303 1.2×	24	1.9k
Steven S. Chua United States	16	662 0.7×	374 0.5×	663 1.2×	413 1.1×	276 1.1×	29	1.6k
Cindy Kunne Netherlands	25	889 0.9×	719 1.1×	513 0.9×	186 0.5×	339 1.3×	35	1.7k
Graham P. Hayhurst United Kingdom	16	497 0.5×	516 0.8×	846 1.6×	371 0.9×	495 1.9×	19	1.9k
Mizuho Une Japan	22	947 0.9×	554 0.8×	542 1.0×	161 0.4×	215 0.8×	86	1.5k
Hirdesh Uppal United States	19	1.0k 1.0×	414 0.6×	572 1.1×	435 1.1×	242 0.9×	33	2.0k
Ann L. Craddock United States	10	1.2k 1.2×	813 1.2×	430 0.8×	153 0.4×	308 1.2×	15	1.7k
M Ananthanarayanan United States	16	1.5k 1.5×	1.1k 1.5×	484 0.9×	276 0.7×	477 1.8×	26	2.1k
Ying Mu United States	14	425 0.4×	312 0.5×	361 0.7×	406 1.0×	222 0.9×	23	1.2k
Thomas A. Kocarek United States	29	704 0.7×	356 0.5×	776 1.4×	1.1k 2.9×	143 0.5×	78	2.1k

Countries citing papers authored by Andrew M. Anisfeld

Since Specialization

Citations

This map shows the geographic impact of Andrew M. Anisfeld's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Andrew M. Anisfeld with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Andrew M. Anisfeld more than expected).

Fields of papers citing papers by Andrew M. Anisfeld

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Andrew M. Anisfeld. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Andrew M. Anisfeld. The network helps show where Andrew M. Anisfeld may publish in the future.

Co-authorship network of co-authors of Andrew M. Anisfeld

This figure shows the co-authorship network connecting the top 25 collaborators of Andrew M. Anisfeld. A scholar is included among the top collaborators of Andrew M. Anisfeld based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Andrew M. Anisfeld. Andrew M. Anisfeld is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Curtis, Jeffrey R., Richard Zhang, Sriram Krishnaswami, et al.. (2016). Use of a risk characterisation approach to contextualise the safety profile of new rheumatoid arthritis treatments: a case study using tofacitinib. Clinical Rheumatology. 36(3). 683–688. 4 indexed citations

Keystone, Edward, Andrew M. Anisfeld, Sarika Ogale, Jenny Devenport, & Jeffrey R. Curtis. (2014). Continued Benefit of Tocilizumab Plus Disease-modifying Antirheumatic Drug Therapy in Patients with Rheumatoid Arthritis and Inadequate Clinical Responses by Week 8 of Treatment. The Journal of Rheumatology. 41(2). 216–226. 6 indexed citations

Peterfy, Charles, P.J. Countryman, Annarita Gabriele, et al.. (2011). Magnetic Resonance Imaging in Rheumatoid Arthritis Clinical Trials: Emerging Patterns Based on Recent Experience. The Journal of Rheumatology. 38(9). 2023–2030. 17 indexed citations

Anisfeld, Andrew M., Heidi R. Kast-Woelbern, Hans C. Lee, et al.. (2004). Activation of the nuclear receptor FXR induces fibrinogen expression: a new role for bile acid signaling. Journal of Lipid Research. 46(3). 458–468. 33 indexed citations

Downes, Michael, Mark A. Verdecia, Anthony J. Roecker, et al.. (2003). A Chemical, Genetic, and Structural Analysis of the Nuclear Bile Acid Receptor FXR. Molecular Cell. 11(4). 1079–1092. 310 indexed citations

Anisfeld, Andrew M., Heidi R. Kast-Woelbern, Stacey A. Jones, et al.. (2003). Syndecan-1 Expression Is Regulated in an Isoform-specific Manner by the Farnesoid-X Receptor. Journal of Biological Chemistry. 278(22). 20420–20428. 74 indexed citations

Kast-Woelbern, Heidi R., Bryan Goodwin, Paul T. Tarr, et al.. (2002). Regulation of Multidrug Resistance-associated Protein 2 (ABCC2) by the Nuclear Receptors Pregnane X Receptor, Farnesoid X-activated Receptor, and Constitutive Androstane Receptor. Journal of Biological Chemistry. 277(4). 2908–2915. 723 indexed citations breakdown →

Mak, Puiying A., Heidi R. Kast-Woelbern, Andrew M. Anisfeld, & Peter A. Edwards. (2002). Identification of PLTP as an LXR target gene and apoE as an FXR target gene reveals overlapping targets for the two nuclear receptors. Journal of Lipid Research. 43(12). 2037–2041. 106 indexed citations

Edwards, Peter A., Heidi R. Kast-Woelbern, & Andrew M. Anisfeld. (2002). BAREing it all: the adoption of LXR and FXR and their roles in lipid homeostasis. Journal of Lipid Research. 43(1). 2–12. 323 indexed citations

10.

Kast-Woelbern, Heidi R., Catherine Nguyen, Andrew M. Anisfeld, Johan Ericsson, & Peter A. Edwards. (2001). CTP:phosphocholine cytidylyltransferase, a new sterol- and SREBP-responsive gene. Journal of Lipid Research. 42(8). 1266–1272. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact